Supreme Court Overturns Drug Calibration Patents, Creating Confusion In Biotech Realm
This article was originally published in The Pink Sheet Daily
Executive Summary
The court’s finding that Prometheus’ drug calibration test is unpatentable has left the biotech community reeling with uncertainty as to whether method of treatment claims, particularly those involving biomarkers, will be patent eligible.
You may also be interested in...
Federal Circuit Tosses Diagnostic Patent, Spurring Biopharma Calls For Congressional Action
A divided panel finds Athena Diagnostics' patent on method to diagnose myasthenia gravis is invalid; in dissent, Judge Newman cites industry concerns that the decision will deter development of new diagnostic methods.
US Supreme Court Declines Review Of False Claims Act, PCSK9, Hep C Patents
Gilead disputed Campie FCA decision, Amgen challenged Repatha ruling, and Merck challenged "unclean hands" defense against damages. Patent and Trademark Office wants court to determine if its attorneys' fees should be covered by patent applicants challenging its decisions.
Patentability Of Biotech Inventions Remain Uncertain As Supreme Court Declines Case
Multiple health-care stakeholders had asked the high court to take up the case of Sequenom v. Ariosa to clarify the patentability of a biotech patent. Now the Federal Circuit's interpretation that, firms say, leaves too many innovations unprotected continues to hold sway.